The company said it completed the public offering of Floating Rate Notes due 2026 and 8 series of fixed-rate notes on February 22, 2024. The principal amount of the series ranged from $500,000,000 to $2,750,000,000.

1. 01

   The company said it completed the public offering of Floating Rate Notes due 2026 and 8 series of fixed-rate notes on February 22, 2024. The principal amount of the series ranged from $500,000,000 to $2,750,000,000.

2. 02

   BMS said it intends to use part of the net proceeds from the offering to fund the cash consideration for its acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., along with related fees and expenses. It said it expects to use any remaining net proceeds for general corporate purposes.

3. 03

   The company said that if the Karuna acquisition is not completed by June 30, 2025, or by the later date to which the End Date is extended, plus 5 business days, it will be required to redeem each series of notes other than the 2034, 2044, 2054 and 2064 notes at a price equal to 101% of principal plus accrued and unpaid interest. The offering is not contingent on completion of the acquisitions.

4. 04

   The company said the Floating Rate Notes bear interest at Compounded SOFR plus 0.490%, and the fixed rate notes bear interest at 4.900% to 5.650% per year. The notes mature between February 20, 2026 and February 22, 2064.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.